| Name | Vofopitant |
| Description | Vofopitant (GR 205171) is a potent NK1 receptor antagonist with anxiolytic and antiemetic activity for the study of post-traumatic stress disorder (PTSD). |
| In vitro | Co-administration of paroxetine (4 mg/kg; i.p.) with the NK1 receptor antagonists, Vofopitant/GR205171 (30 mg/kg; i.p.) or L733060 (40 mg/kg; i.p.), potentiated the effects of paroxetine on cortical [5-HT]ext in wild-type mice, whereas GR205171 (30 mg/kg; i.p.) had no effect on paroxetine-induced increase in cortical [5-HT]ext in NK1 receptor knock-out mice. When GR205171 (300 micro mol/L) was perfused by 'reverse microdialysis' into the dorsal raphe nucleus, it potentiated the effects of paroxetine on cortical [5-HT]ext, and inhibited paroxetine-induced increase in [5-HT]ext in the dorsal raphe nucleus[2]. |
| In vivo | In a T-maze experiment, Vofopitant (GR205171, 30 mg/kg, subcutaneously) enhances the selection of a 25-second delayed reward[3]. Furthermore, when administered intraperitoneally at the same dosage, Vofopitant elevates extracellular serotonin (5-HT) levels in the frontal cortex of wild-type mice treated with paroxetine, but not in untreated wild-type or in NK1 receptor knockout mice also treated with paroxetine[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Keywords | Vofopitant | GR205171 | GR-205171 |
| Inhibitors Related | Lanepitant 2HCl | Rolapitant | Ezlopitant | (R)-CJ 11974 | N-Acetyl-L-tryptophan | Netupitant | Aprepitant | Befetupitant | Fosaprepitant dimeglumine | Maropitant |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Drug Repurposing Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
